853066-73-6

Usage

Uses

Used in Pharmaceutical Industry:
Tributyl[4-(4-fluorophenyl)-6-isopropyl-2-[(2-n-Methyl-n-Methyl sulfonyl)aMino]pyriMidine-5-yl-Methyl]phosphine broMine is used as a synthetic intermediate for the development of new drug candidates. Its ability to modify molecular structures makes it a valuable tool in the creation of potential therapeutic agents.
Used in Organic Chemistry:
In the realm of organic chemistry, Tributyl[4-(4-fluorophenyl)-6-isopropyl-2-[(2-n-Methyl-n-Methyl sulfonyl)aMino]pyriMidine-5-yl-Methyl]phosphine broMine serves as a reagent for the modification of molecules. Its role in enhancing the properties of organic compounds is crucial for advancing chemical research and development.
Given the intricate nature of this chemical, it is imperative to handle Tributyl[4-(4-fluorophenyl)-6-isopropyl-2-[(2-n-Methyl-n-Methyl sulfonyl)aMino]pyriMidine-5-yl-Methyl]phosphine broMine with care and to adhere to stringent safety protocols to ensure the safety of both individuals and the environment.

Upstream product

• 998-40-3 tributylphosphine 
• 1416000-55-9 N-(5-(bromomethyl)-4-(2-bromopropan-2-yl)-6-(4-fluorophenyl)pyrimidin-2-yl)-N-methylmethanesulfonamide 
• 925422-06-6 N-[5-chloromethyl-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-2-yl]-N-methyl-methanesulfonamide 
• 799842-07-2 N-[5-(bromomethyl)-4-(4-fluorophenyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 147118-30-7 ethyl 2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-carboxylic acid 
• 147118-36-3 N-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 

Relevant academic research and scientific papers

Application of flow photochemical bromination in the synthesis of a 5-bromomethylpyrimidine precursor of rosuvastatin: Improvement of productivity and product purity

In this report we present a flow photochemical bromination of a 5-methyl-substituted pyrimidine precursor of rosuvastatin. The study demonstrated that the reaction productivity can be increased markedly with a flow-mode approach compared to a batch-mode synthesis. Indeed, reaction times can be significantly shortened from a range of hours to a range of minutes. Moreover, in addition to process intensification, the study demonstrated that significantly lower overall levels of side products are obtained when photochemical bromination is conducted in a flow mode.

PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF

The present invention provides an improved process for preparing HMG-CoA reductase inhibitors such as rosuvasatin calcium, fluvastatin sodium, and pitavastatin calcium under a mild condition, using a novel amide-bond-containing compound having R2-N-O-R1 moiety as a key intermediate. And also, the present invention provides the novel compound, an intermediate useful for the preparation thereof, and a process for the preparation thereof.

PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM

Present invention represents process for the preparation of HMG-CoA reductsase inhibitors, in particular rosuvastatin calcium introducing L-malic acid as the source of chirality for the side chain

Process for the preparation of pyrimidine derivatives

An improved process for the preparation of pyrimidine derivatives is provided comprising reacting a Wittig reagent of the general formula wherein R is an alkyl of from 1 to 10 carbon atoms, aryl or arylalkyl, R1 is a substituted or unsubstituted hydrocarbon group, R2 and R3 are the same or different and are hydrogen or a substituted or unsubstituted hydrocarbon group; Z is sulfur, oxygen, sulfonyl, or imino which may be substituted by formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, amino substituted by sulfonyl or alkylsulfonyl, and sulfonyl substituted by alkyl, amino or alkylamino and X is a halogen; with an aldehyde of the general formula wherein R4 is hydrogen, a lower alkyl or a cation capable of forming a non-toxic pharmaceutically acceptable salt and each R5 are the same or different and are hydrogen or a hydrolyzable protecting group, or each R5, together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group, or each R5 is bonded to the same substituent which is bonded to each oxygen atom to form a hydrolyzable protecting group; in the presence of a base.